Developing a new treatment for non-small cell lung cancer and other solid tumors
VEL-03: IND-enabling development of a novel therapeutic approach for treatment of non-small cell lung cancer and other solid tumors
['FUNDING_SBIR_2'] · VELORUM THERAPEUTICS INC. · NIH-11066672
This study is testing a new treatment called VEL-03 for people with non-small cell lung cancer, which aims to help fight the cancer while being gentle on healthy cells, and it will be used alongside radiation and a common chemotherapy drug to see if it can improve results for patients.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VELORUM THERAPEUTICS INC. (nih funded) |
| Locations | 1 site (PLANO, UNITED STATES) |
| Trial ID | NIH-11066672 on ClinicalTrials.gov |
What this research studies
This research focuses on a novel therapy called VEL-03, designed to target the metabolism of cancer cells, particularly in non-small cell lung cancer (NSCLC). The approach involves disrupting heme uptake, which is crucial for cancer growth, while minimizing damage to normal cells. The study will evaluate the effectiveness of VEL-03 in combination with radiation therapy and Cisplatin, and will also work on scaling up the manufacturing process for clinical use. Patients may benefit from this innovative treatment that aims to improve outcomes for those with hard-to-treat cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer or other solid tumors who have limited treatment options.
Not a fit: Patients with early-stage cancers or those who do not have solid tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with non-small cell lung cancer and other solid tumors.
How similar studies have performed: Other research has shown promise in targeting cancer metabolism, suggesting that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
PLANO, UNITED STATES
- VELORUM THERAPEUTICS INC. — PLANO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHOWALTER, RICHARD EDWARD — VELORUM THERAPEUTICS INC.
- Study coordinator: SHOWALTER, RICHARD EDWARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, Cancer Cause, Cancer Cell Growth, cancer cell metabolism, Cancer Etiology